97 related articles for article (PubMed ID: 24898648)
1. Alzheimer's disease-like pattern of (18)F-FDG uptake during a hyperglycemic state and negative (11)C-PiB binding in a patient with mild cognitive impairment.
Ishibashi K; Miura Y; Oda K; Ishiwata K; Ishii K
J Alzheimers Dis; 2014; 42(2):385-9. PubMed ID: 24898648
[TBL] [Abstract][Full Text] [Related]
2. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
3. Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment.
Apostolova I; Lange C; Suppa P; Spies L; Klutmann S; Adam G; Grothe MJ; Buchert R;
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1417-1422. PubMed ID: 29502311
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
[TBL] [Abstract][Full Text] [Related]
5. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632
[TBL] [Abstract][Full Text] [Related]
6. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.
Ossenkoppele R; Tolboom N; Foster-Dingley JC; Adriaanse SF; Boellaard R; Yaqub M; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):990-1000. PubMed ID: 22441582
[TBL] [Abstract][Full Text] [Related]
8. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment.
Zhang S; Han D; Tan X; Feng J; Guo Y; Ding Y
Int J Clin Pract; 2012 Feb; 66(2):185-98. PubMed ID: 22257044
[TBL] [Abstract][Full Text] [Related]
10. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease.
Kadir A; Almkvist O; Forsberg A; Wall A; Engler H; Långström B; Nordberg A
Neurobiol Aging; 2012 Jan; 33(1):198.e1-14. PubMed ID: 20688420
[TBL] [Abstract][Full Text] [Related]
11. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
12. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment.
Brück A; Virta JR; Koivunen J; Koikkalainen J; Scheinin NM; Helenius H; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1567-72. PubMed ID: 23801168
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage.
Morbelli S; Bauckneht M; Arnaldi D; Picco A; Pardini M; Brugnolo A; Buschiazzo A; Pagani M; Girtler N; Nieri A; Chincarini A; De Carli F; Sambuceti G; Nobili F
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2073-2083. PubMed ID: 28785843
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
[TBL] [Abstract][Full Text] [Related]
15. Relationship between Alzheimer disease-like pattern of 18F-FDG and fasting plasma glucose levels in cognitively normal volunteers.
Ishibashi K; Onishi A; Fujiwara Y; Ishiwata K; Ishii K
J Nucl Med; 2015 Feb; 56(2):229-33. PubMed ID: 25572094
[TBL] [Abstract][Full Text] [Related]
16. The use of PIB-PET as a dual pathological and functional biomarker in AD.
Forsberg A; Engler H; Blomquist G; Långström B; Nordberg A
Biochim Biophys Acta; 2012 Mar; 1822(3):380-5. PubMed ID: 22115832
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
[TBL] [Abstract][Full Text] [Related]
18. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD).
Bauckneht M; Chincarini A; Piva R; Arnaldi D; Girtler N; Massa F; Pardini M; Grazzini M; Efeturk H; Pagani M; Sambuceti G; Nobili F; Morbelli S
Alzheimers Res Ther; 2018 Apr; 10(1):35. PubMed ID: 29615111
[TBL] [Abstract][Full Text] [Related]
19. Amyloid imaging with (11)C-PIB PET/CT and glucose metabolism with (18)F-FDG PET/CT in a study on cognitive impairment in the clinical setting.
Banzo I; Jiménez-Bonilla J; Ortega-Nava F; Quirce R; Martínez-Rodríguez I; de Arcocha-Torres M; Rodríguez E; Vázquez JL; Sánchez PJ; Martínez-Amador N; Ibañez-Bravo S; Carril JM
Nucl Med Commun; 2014 Mar; 35(3):238-44. PubMed ID: 24240196
[TBL] [Abstract][Full Text] [Related]
20. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.
Forsberg A; Almkvist O; Engler H; Wall A; Långström B; Nordberg A
Curr Alzheimer Res; 2010 Feb; 7(1):56-66. PubMed ID: 20205671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
